Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares gapped down before the market opened on Wednesday. The stock had previously closed at $16.00, but opened at $14.90. Ono Pharmaceutical shares last traded at $14.90, with a volume of 1,000 shares.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Friday, September 4th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Ono Pharmaceutical Trading Down 6.9%

The firm has a market capitalization of $7.00 billion, a price-to-earnings ratio of 14.19 and a beta of 0.38. The company has a fifty day moving average price of $15.06 and a two-hundred day moving average price of $14.87. The company has a current ratio of 3.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.08.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.